Concepedia

Mark Kipnes

MK

Statistics

Publications

59

Citations

7.1K

H-Index

37

Active since

1987

Affiliations

Diabetes & Glandular Disease Clinic(Current)

University of Washington

Atlanta Diabetes Associates

AMCR Institute

Merck & Co., Inc., Rahway, NJ, USA (United States)

Mark Kipnes is an author at Diabetes & Glandular Disease Clinic specializing in medicine, diabetes mellitus, and diabetology.

Publications per year

1987–2025

59

Publications

59

Efficacy and Safety of the Farnesoid X Receptor Agonist Obeticholic Acid in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Sunder Mudaliar, Robert R. Henry, Arun J. Sanyal et al. · Gastroenterology · 2013 · 915 citations

, , +12

Effect of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin as Monotherapy on Glycemic Control in Patients With Type 2 Diabetes

Pablo Aschner, Mark Kipnes, Jared Lunceford et al. · Diabetes Care · 2006 · 881 citations

, , +17

Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

Kjeld Hermansen, Mark Kipnes, Edmund Luo et al. · Diabetes Obesity and Metabolism · 2007 · 526 citations · Full text

, , +17

Effect of Single Oral Doses of Sitagliptin, a Dipeptidyl Peptidase-4 Inhibitor, on Incretin and Plasma Glucose Levels after an Oral Glucose Tolerance Test in Patients with Type 2 Diabetes

Gary Herman, Arthur Bergman, Catherine Stevens et al. · The Journal of Clinical Endocrinology & Metabolism · 2006 · 499 citations

, , +17

Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome

Maria Fleseriu, Beverly M. K. Biller, James W. Findling et al. · The Journal of Clinical Endocrinology & Metabolism · 2012 · 484 citations · Full text

, , +17

1–5 of 59